{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-290445","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2022-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.578227+00:00","generated_at":"2026-06-21T14:30:47.122417+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"XOMA acquires ebopiprant from ObsEva for $15M cash plus milestone earn-outs","bullets":["XOMA pays $15M cash at closing to ObsEva for ebopiprant; assumes IP estate and all license agreements including Organon sublicense.","XOMA eligible for up to $475M in development, regulatory, and sales milestones from Organon; will pay ObsEva up to $98M of those.","Upon commercialization, XOMA receives low- to mid-teen royalties from Organon and pays mid-single-digit royalty to Merck KGaA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-290445","json":"https://secwatch.observer/filing/0001193125-22-290445.json","markdown":"https://secwatch.observer/filing/0001193125-22-290445.md","text":"https://secwatch.observer/filing/0001193125-22-290445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312522290445/0001193125-22-290445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312522290445/d396302d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T14:30:47.122417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ff2a52aa652b2017e3e3580109f1fa1d0785d1e","claim":"XOMA Royalty Corp entered into Intellectual Property Acquisition Agreement with ObsEva SA valued at $15 million upfront plus up to $98 million in milestone payments (effective 2022-11-21).","evidence_excerpt":"On November 21, 2022, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into an intellectual property acquisition agreement (the “Agreement”) with ObsEva, SA, a Swiss biotech company (“ObsEva”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312522290445/0001193125-22-290445-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"ObsEva SA"},{"label":"Value","value":"$15 million upfront plus up to $98 million in milestone payments"},{"label":"Effective","value":"2022-11-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}